Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro

Pharmacogenetics and Genomics

Volumn 17, Issue 1, 2007, Pages 1-10

  Tanimoto, Keiji ^a   Kaneyasu, Mika ^a   Shimokuni, Tatsushi ^a   Hiyama, Keiko ^a   Nishiyama, Masahiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Carboxylesterase; CES1A1; CES1A2; CPT 11; Nucleotide sequence

Indexed keywords

BIOLOGICAL MARKER; CARBOXYLESTERASE; CARBOXYLESTERASE 1A1; CARBOXYLESTERASE 1A2; IRINOTECAN; ISOENZYME; MESSENGER RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESPONSE; ENZYME ANALYSIS; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE HOMOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CELL LINE, TUMOR; CLONING, MOLECULAR; GENOTYPE; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; PROMOTER REGIONS (GENETICS); PROTEIN ISOFORMS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 33846628102     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000230110.18957.50     Document Type: Article

References (16)

1. Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 1998; 38:257-288.
2. Rooseboom M, Commandeur JNM, Vermeulen NPE. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 2004; 56:53-102.
3. Sanghani SP, Quinney SK, Fredenburg TB, Sun Z, Davis WI, Murry DJ, et al. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Cancer Res 2003; 9:4983-4991.
4. Xu G, Zhang W, Ma MK, McLeod L. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002; 8:2605-2611.
5. Kojima A, Hackett NR, Crystal RG. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of human carboxylesterase cDNA. Cancer Res 1998; 58:4368-4374.
6. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000; 60:1189-1192.
7. Wu MH, Yan B, Humerickhouse R, Dolan ME. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res 2002; 8:2696-2700.
8. Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 2004; 84:661-668.
9. Satoh H, Hiyama K, Takeda M, Awaya Y, Watanabe K, Ihara Y, et al. Telomere shortening in peripheral blood cells was related with aging but not with white blood cell count. Jpn J Human Genet 1996; 41:413-417.
10. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
11. Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtaki M, Yoshida K, et al. Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer 2004; 111:617-626.
12. Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, Bosron WF. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N- (5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 2004; 32:505-511.
13. Cecchin E, Corona G, Masier S, Biason P, Cattarossi G, Frustaci S, et al. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the Irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 2005; 19:6901-6907.
14. Bencharit S, Morton CL, Howard-Williams EL, Danks MK, Potter PM, Redinbo MR. Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol 2002; 9:337-342.
15. Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004; 90:8-11.
16. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9:3246-3253.